CURRENT Med Diag & Treatment 17+
Guide to Internal Medicine
Skyscape Medpresso Inc
-
- Free
- Offers In-App Purchases
Screenshots
Description
New 2023 Update - #1 annual Internal Medicine Guide -1000+ diseases and disorders including concise, yet thorough synopsis of diagnosis and treatment
"Try before you buy" - Download the FREE App, which includes sample content. In-App purchase required to unlock all content.
The #1 annual internal medicine guide extensively revised and updated
The most popular annual guide of its kind, this updated edition presents the most important diagnostic and treatment recommendations as well as the most useful new clinical developments in every field of adult medicine.
For 60+ years, CURRENT Medical Diagnosis & Treatment has been delivering the authoritative information that students, residents, and clinicians need to build their medical knowledge, expertise, and confidence. Written by top experts in their fields, this unmatched guide enables you to find the answers you need quickly and easily. It provides:
- Coverage of more than 1,000 diseases and disorders
- Comprehensive approach to patient care, focusing on diagnostic tools for day-to-day practice
- Hundreds of drug treatment tables for quick access to indexed trade names and updated drug prices
- Diagnostic and treatment algorithms to present important information at a glance
- Carefully curated, updated references to provide peer-reviewed, evidence-based information, and PMID numbers for quick online access
- Annual update on dynamic viral infections, including SARS-CoV-2/COVID-19 and HIV/AIDS
- Hundreds of full-color photographs, illustrations, and algorithms
KEY FEATURES
- Medical advances up to time of annual publication
- Detailed presentation of internal medicine disciplines, plus primary care topics in gynecology, obstetrics, dermatology, ophthalmology, otolaryngology, psychiatry, neurology, toxicology, urology, geriatrics, orthopedics, women’s health, sexual and gender minority health, preventive medicine, and palliative care
- Concise format, facilitating efficient use in any practice setting
- More than 1000 diseases and disorders
- Specific disease prevention information
- Easy access to medication dosages, with trade names indexed and current costs updated in each annual edition
- Recent references, with unique identifiers (PubMed, PMID numbers) for rapid downloading of article abstracts and, in some instances, full-text reference articles
Content licensed from printed edition ISBN 10: 1264687745
Content licensed from printed edition ISBN 13: 9781264687749
SUBSCRIPTION :
Please purchase a yearly auto-renewing subscription to receive content access and available updates.
Yearly auto-renewing payments- $59.99
Payment will be charged to your iTunes Account at confirmation of purchase. Subscription automatically renews unless auto-renew is turned off at least 24-hours before the end of the current period. Subscription may be managed by the user and auto-renewal can be disabled at any time by going to your device “Settings” and tapping “iTunes & App Store”. Any unused portion of a free trial period will be forfeited when you purchase a subscription, where applicable."
If you have any questions or comments, email us any time: customersupport@skyscape.com or call 508-299-3000
Privacy Policy - https://www.skyscape.com/terms-of-service/privacypolicy.aspx
Terms and Conditions - https://www.skyscape.com/terms-of-service/licenseagreement.aspx
Author(s): Maxine Papadakis, Stephen McPhee, Michael Rabow, Kenneth McQuaid
Publisher: The McGraw-Hill Companies, Inc.
What’s New
Version 5.0.10
NEW TO THIS EDITION
- Ongoing concerted effort to address and remove unconscious bias
- List of Common Abbreviations used in CMDT
- New section on opioids for pain management
- Overhauled organization of Dermatology topics to better reflect categorization of conditions and lesions
- Expanded section of interventional therapies to manage chronic pain
- Updated USPSTF lung cancer screening recommendations using low-dose CT
- New prognostic systems for primary myelofibrosis: GIPSS and MIPSSv2
- Discussion of the use of DOACs in patients with morbid obesity who require antithrombotic therapy
- Updated section on osmotic laxatives to treat chronic constipation
- Ozanimod approved for the treatment of moderate to severe ulcerative colitis
- Landmark change in staging female breast carcinoma modifying anatomic stage and adding prognostic stage
- New medications for treating metastatic breast cancer (olaparib, talazoparib, palbociclib, ribociclib, and abemaciclib)
- New recommendations on treating cholestasis of pregnancy
- Updated criteria for diagnosing systemic lupus erythematosus to include antinuclear antibody measurement
- New medications for active lupus nephritis, including voclosporin used with mycophenolate mofetil as well as belimumab
- Anifrolumab is approved for nonrenal lupus when standard therapies fail
- New guidelines for diagnosing polyarteritis nodosa
- New American College of Rheumatology/Vasculitis Foundation recommendations for the treatment of granulomatosis with polyangiitis
- A newly described genetic syndrome, VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) in the differential diagnosis of relapsing polychondritis
- Discussion of the role of left atrial appendage closure in preventing stroke and systemic embolization
- Aducanumab (anti-amyloid therapy) is approved by the US FDA for the treatment of Alzheimer disease
- Extensive revision of the Thyroiditis section in Endocrine Disorders topic
- Substantial revision of the Nutritional Support section in the Nutritional Disorders & Obesity topic
- Substantial revision in the HIV Infection & AIDS chapter, including updates in the available therapeutic regimens
- Rewritten SARS-CoV-2 section and inclusion of SARS-CoV-2 information relevant to specific chapters throughout the textbook
- Extensive revision of Sexual & Gender Minority Health chapter, including sections on family planning and health care for transgender and gender diverse persons
Subscriptions
App Privacy
The developer, Skyscape Medpresso Inc, indicated that the app’s privacy practices may include handling of data as described below. For more information, see the developer’s privacy policy.
Data Not Linked to You
The following data may be collected but it is not linked to your identity:
- User Content
- Search History
- Identifiers
- Usage Data
- Diagnostics
Privacy practices may vary based on, for example, the features you use or your age. Learn More
Information
- Provider
- Skyscape Medpresso Inc
- Size
- 10.5 MB
- Category
- Medical
- Compatibility
-
- iPhone
- Requires iOS 12.0 or later.
- iPad
- Requires iPadOS 12.0 or later.
- iPod touch
- Requires iOS 12.0 or later.
- Mac
- Requires macOS 10.15 or later.
- Apple Vision
- Requires visionOS 1.0 or later.
- Languages
-
English
- Age Rating
- 17+ Frequent/Intense Medical/Treatment Information Infrequent/Mild Alcohol, Tobacco, or Drug Use or References
- Copyright
- © (c) 1998-2024 Skyscape Medpresso, Inc. All rights reserved.
- Price
- Free
- In-App Purchases
-
- Curr Med Diag Treat 15%off Sub $55.99
- Curr Med Diag Treat 20%off Sub $51.99
- Curr Med Diag Treat 25%off Sub $48.99
- Curr Med Diag Treat 25%off Sub $44.99
- Curr Med Diag Treat 20%off Sub $47.99
- Curr Med Diag Treat 15%off Sub $50.99
- Curr Med Diag Treat 1Y Sub Off $47.99
- Curr Med Diag Treatment 1Y Sub $64.99
- Curr Med Diag Treatment 6M Sub $49.99
- Curr Med Diag Treatment 3M Sub $37.99